Abbott Laboratories announced positive clinical trial results for its Amulet 360 Left Atrial Appendage (LAA) occluder. The VERITAS Study showed top-tier performance for patients with paroxysmal and persistent AFib, with 93.9% achieving complete LAA closure after 45 days and a 99.8% implant success rate. Full results for this device are expected in 2027.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Abbott Laboratories (ABT) Announces Positive Results for Amulet 360 Left Atrial Appendage (LAA) Occlude
Abbott Laboratories announced positive clinical trial results for its Amulet 360 Left Atrial Appendage (LAA) occluder. The VERITAS Study showed top-tier performance for patients with paroxysmal and persistent AFib, with 93.9% achieving complete LAA closure after 45 days and a 99.8% implant success rate. Full results for this device are expected in 2027.